Business
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company's Cambridge, Massachusetts office.
About this update from Insilico Medicine Cayman Topco
[{"type":"text","content":"CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company's Cambridge, Massachusetts office.","length":490,"tagName":"p"},{"type":"text","content":"In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico's oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company's growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies.","length":489,"tagName":"p"},{"type":"text","content":"Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials.","length":784,"tagName":"p"},{"type":"text","content":"She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration.","...